Peptide pharmacy quality: what to ask after the HHS draft

The Federal Register notice identifies the linked policy as a draft and schedules publication for October 30, 2026. As of this article’s October 28 date, its proposed safeguards should not be presented as a completed inspection of a pharmacy or certification of a particular batch. A statement that a business follows “the new peptide policy” deserves a specific explanation.

Ask which current requirements the pharmacy is relying on and which exact product the explanation concerns. This keeps the discussion focused on verifiable preparation and dispensing details rather than treating a federal document as a universal quality badge.

The HHS draft distinguishes the original manufacturer from a repacker or distributor. It specifies FDA registration, CGMP compliance and other requirements for the original manufacturer, with its physical facility location on the certificate of analysis. It also describes vendor and COA validation responsibilities for registered repackers, relabelers, or resellers.

The practical question is whether the pharmacy can trace the ingredient to its original manufacturing facility and explain its verification process. The document does not require all ingredients to be made in the United States. “Registered” and “American made” are different claims, and neither alone proves that an individual treatment is effective.

A COA reports specified tests and results for material associated with a batch. The policy proposes testing consistent with Appendix B, including identity, purity, potency, and contaminant controls. A useful discussion asks what was tested, which batch the document concerns, and who verified that the documentation matches the material used.

The FDA discussion of component controls and COAs explains why supplier information must sit within appropriate verification and quality procedures. A COA is not a clinical trial, an FDA drug approval, or a promise that side effects cannot occur. Avoid judging a medicine solely by a prominent purity percentage on a sales page.

The draft specifies the statement “This is a compounded drug product. Not for resale.” It also addresses reporting information. Before using any prescribed medicine, ask the pharmacist to explain the label, storage, expiration or beyond-use information, and what to do if the packaging appears damaged or the contents look unexpected.

Keep the dispensed label and paperwork so the care team can identify the preparation if a concern arises. Do not transfer medication to an unmarked container or change handling instructions based on generic online advice. A label question should be resolved with the dispensing pharmacy before you improvise a solution.

The draft describes reporting of products, serious adverse events, and product quality issues to FDA and relevant states. It specifies serious-event reporting regardless of whether the event is considered drug-related. Ask the pharmacy and prescriber how patients should report a suspected problem and which details they need.

The FDA compounding questions and answers explains that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing in the way approved drugs are. Proposed safeguards do not remove that distinction. For concerning symptoms, seek appropriate medical advice rather than waiting for a supplier to interpret a COA. For the broader context, read the policy overview.